Probing the local conformational change of α1-antitrypsin

Protein Science

Volumn 16, Issue 9, 2007, Pages 1842-1850

  Baek, Je Hyun ^a,b   Im, Hana ^c   Kang, Un Beom ^a,b   Ki, Moon Seong ^b   Lee, Cheolju ^a   Kim, Joon ^b   Yu, Myeong Hee ^a  

^a Korea Institute of Science and Technology   (South Korea)

^b Korea University   (South Korea)

^c Sejong University   (South Korea)

Author keywords

1 antitrypsin; Conformational change; Disulfide locking; Loop sheet polymerization; Protein engineering; Serpin

Indexed keywords

ALPHA 1 ANTITRYPSIN; PANCREATIC ELASTASE; PROTEINASE; RECOMBINANT PROTEIN;

ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME INHIBITION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN ENGINEERING; SITE DIRECTED MUTAGENESIS; THERMOSTABILITY;

ALPHA 1-ANTITRYPSIN; AMINO ACID SUBSTITUTION; ANILINO NAPHTHALENESULFONATES; ANIMALS; BINDING SITES; CYSTEINE; DISULFIDES; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME STABILITY; ESCHERICHIA COLI; FLUORESCENT DYES; HEAT; HUMANS; KINETICS; MASS SPECTROMETRY; MODELS, MOLECULAR; OXIDATION-REDUCTION; PANCREATIC ELASTASE; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN ENGINEERING; PROTEIN STRUCTURE, SECONDARY; RECOMBINANT PROTEINS; SERINE PROTEINASE INHIBITORS; SWINE;

EID: 34548463041     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1110/ps.072911607     Document Type: Article

References (44)

1. 1-Antitrypsin replacement therapy: Current status. Curr. Opin. Pulm. Med. 12: 125-131.
2. Aulak, K.S., Eldering, E., Hack, C.E., Lubbers, Y.P., Harrison, R.A., Mast, A., Cicardi, M., and Davis 3rd, A.E. 1993. A hinge region mutation in C1-inhibitor (A436T) results in nonsubstrate-like behavior and in polymerization of the molecule. J. Biol. Chem. 268: 18088-18094.
3. 1- antichymotrypsin at 2.7 Å resolution and its comparison with other serpins. J. Mol. Biol. 218: 595-606.
4. 1-antichymotrypsin. J. Biol. Chem. 255: 3931-3934.
5. 1-helix F and the main part of serpins, based upon identification of the epitope of plasminogen activator inhibitor type 1 neutralizing antibodies. J. Biol. Chem. 275: 6375-6380.
6. Bruce, D., Perry, D.J., Borg, J.Y., Carrell, R.W., and Wardell, M.R. 1994. Thromboembolic disease due to thermolabile conformational changes of antithrombin Rouen-VI (N187D). J. Clin. Invest. 94: 2265-2274.
7. Bruch, M., Weiss, V., and Engel, J. 1988. Plasma serine proteinase inhibitors exhibit major conformational changes and a large increase in conformational stability upon cleavage at their reactive sites. J. Biol. Chem. 263: 16626-16630.
8. Cabrita, L.D., Dai, W., and Bottomley, S.P. 2004. Different conformational changes within the F-helix occur during serpin folding, polymerization, and proteinase inhibition. Biochemistry 43: 9834-9839.
9. Cabrita, L.D., Whisstock, J.C., and Bottomley, S.P. 2002. Probing the role of the F-helix in serpin stability through a single tryptophan substitution. Biochemistry 41: 4575-4581.
10. Chang, W.S., Whisstock, J., Hopkins, P.C., Lesk, A.M., Carrell, R.W., and Wardell, M.R. 1997. Importance of the release of strand 1C to the polymerization mechanism of inhibitory serpins. Protein Sci. 6: 89-98.
11. 1-AT. J. Biol. Chem. 274: 9548-9555.
12. Edelhoch, H. 1967. Spectroscopic determination of tryptophan and tyrosine in proteins. Biochemistry 6: 1948-1954.
13. Eijsink, V.G., Bjork, A., Gaseidnes, S., Sirevag, R., Synstad, B., van den Burg, B., and Vriend, G. 2004. Rational engineering of enzyme stability. J. Biotechnol. 113: 105-120.
14. 1-AT reveals targets for rational drug design to prevent conformational disease. Protein Sci. 9: 1274-1281.
15. Gettins, P.G. 2002. The F-helix of serpins plays an essential, active role in the proteinase inhibition mechanism. FEBS Lett. 523: 2-6.
16. Goldenberg, D.P. and Creighton, T.E. 1989. Analysis of protein conformation by gel electrophoresis. In Protein structure: A practical approach, pp. 225-250. IRL Press, Oxford, UK.
17. 1-antichymotrypsin indicates two-stage insertion of the reactive loop. Proc. Natl. Acad. Sci. 97: 67-72.
18. 1-AT for structure and function of serpins. Biochemistry 28: 8951-8966.
19. Hugo, N., Lafont, V., Beukes, M., and Altschuh, D. 2002. Functional aspects of co-variant surface charges in an antibody fragment. Protein Sci. 11: 2697-2705.
20. Huntington, J.A., Read, R.J., and Carrell, R.W. 2000. Structure of a serpin protease complex shows inhibition by deformation. Nature 407: 923-926.
21. Im, H. and Yu, M.H. 2000. Role of K335 in the metastability and function of inhibitory serpins. Protein Sci. 9: 934-941.
22. 1-AT. J. Biol. Chem. 274: 11072-11077.
23. 1-AT polymerization probed by fluorescence spectroscopy. Arch. Biochem. Biophys. 356: 296-300.
24. 1-AT. Biochem. Biophys. Res. Commun. 323: 409-415.
25. 1-AT suppresses the folding defect of the Z-type variant. J. Biol. Chem. 270: 8597-8601.
26. 1- AT expressed as inclusion bodies in Escherichia coli. Biochim. Biophys. Acta 1247: 179-184.
27. 1-AT that confer enhancement in thermal stability. J. Biol. Chem. 269: 9627-9631.
28. Laemmli, U.K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685.
29. 1-AT that play structural and functional roles. Protein Sci. 10: 1446-1453.
30. 1-AT. Nat. Struct. Biol. 3: 497-500.
31. 1-proteinase inhibitor. J. Mol. Biol. 177: 531-557.
32. 1-AT accumulation in the liver. Nature 357: 605-607.
33. McHugh, C.A., Tammariello, R.F., Millard, C.B., and Carra, J.H. 2004. Improved stability of a protein vaccine through elimination of a partially unfolded state. Protein Sci. 13: 2736-2743.
34. Reiter, Y., Brinkmann, U., Lee, B., and Pastan, I. 1996. Engineering antibody Fv fragments for cancer detection and therapy: Disulfide-stabilized Fv fragments. Nat. Biotechnol. 14: 1239-1245.
35. 1-antitrypsin and its association with protease inhibitor function. J. Biol. Chem. 275: 16904-16909.
36. Skinner, R., Chang, W.S., Jin, L., Pei, X., Huntington, J.A., Abrahams, J.P., Carrell, R.W., and Lomas, D.A. 1998. Implications for function and therapy of a 2.9 Å structure of binary-complexed antithrombin. J. Mol. Biol. 283: 9-14.
37. Stein, P.E. and Carrell, R.W. 1995. What do dysfunctional serpins tell us about molecular mobility and disease? Nat. Struct. Biol. 2: 96-113.
38. Stratikos, E. and Gettins, P.G. 1999. Formation of the covalent serpin proteinase complex involves translocation of the proteinase by more than 70 Å and full insertion of the reactive center loop into β-sheet A. Proc. Natl. Acad. Sci. 96: 4808-4813.
39. Tsutsui, Y., Liu, L., Gershenson, A., and Wintrode, P.L. 2006. The conformational dynamics of a metastable serpin studied by hydrogen exchange and mass spectrometry. Biochemistry 45: 6561-6569.
40. Vleugels, N., Gils, A., Bijnens, A.P., Knockaert, I., and Declerck, P.J. 2000. The importance of helix F in plasminogen activator inhibitor-1. Biochim. Biophys. Acta 1476: 20-26.
41. Wei, A., Rubin, H., Cooperman, B.S., and Christianson, D.W. 1994. Crystal structure of an uncleaved serpin reveals the conformation of an inhibitory reactive loop. Nat. Struct. Biol. 1: 251-258.
42. Wilczynska, M., Lobov, S., Ohlsson, P.I., and Ny, T. 2003. A redox-sensitive loop regulates plasminogen activator inhibitor type 2 polymerization. EMBO J. 22: 1753-1761.
43. Wind, T., Jensen, M.A., and Andreasen, P.A. 2001. Epitope mapping for four monoclonal antibodies against human plasminogen activator inhibitor type-1. Eur. J. Biochem. 268: 1095-1106.
44. 1-AT causes a protein folding defect. Nat. Struct. Biol. 2: 363-367.